Magen, Iddo

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 346

Dysregulated miRNA biogenesis downstream of cellular stress and ALS‐causing mutations: a new mechanism for ALS

Emde, A., Eitan, C., Liou, L., Libby, R. T., Rivkin, N., Magen, I., Reichenstein, I., Oppenheim, H., Eilam, R., Silvestroni, A., et al. (2015) · The EMBO Journal

Amyotrophic Lateral Sclerosis ResearchMicroRNA in disease regulation

Cited by 217

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein

Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research

Parkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

Cited by 184

Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer’s pathologies

Malishkevich, A., Amram, N., Hacohen-Kleiman, G., Magen, I., Giladi, E., & Gozes, I. (2015) · Translational Psychiatry

Genetics and Neurodevelopmental DisordersAlzheimer's disease research and treatments

Cited by 109

Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

Benatar, M., Macklin, E. A., Malaspina, A., Rogers, M.-L., Hornstein, E., Lombardi, V., Renfrey, D., Shepheard, S., Magen, I., Cohen, Y., et al. (2024) · eBioMedicine

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research

Cited by 61

Neutrophil to-lymphocyte and platelet-to-lymphocyte ratios as biomarkers for suicidal behavior in children and adolescents with depression or anxiety treated with selective serotonin reuptake inhibitors

Amitai, M., Kaffman, S., Kroizer, E., Lebow, M., Magen, I., Benaroya-Milshtein, N., Fennig, S., Weizman, A., Apter, A., & Chen, A. (2022) · Brain, Behavior, and Immunity

Suicide and Self-Harm StudiesTryptophan and brain disorders

Cited by 51